Identification of Carnitine-Responsive Cardiomyopathy (C001)
|Study Design:||Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
|Official Title:||Identification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness.|
- Serum Carnitine Concentration [ Time Frame: Baseline ] [ Designated as safety issue: No ]Measurement of free and total serum carnitine concentrations will be performed using isotope-dilution mass spectrometry.
- Echocardiographic Measures [ Time Frame: Baseline, every 6m for up to 2 years ] [ Designated as safety issue: No ]
Septal diameter Left Ventricular (LV) mass LV ejection fraction LV end-systolic volume LV end-diastolic measure
- B-Natriuretic Peptide (BNP) [ Time Frame: Baseline, every 6m for up to 2 years ] [ Designated as safety issue: No ]An elevated BNP level is a marker of increased LV filling pressures and LV dysfunction and is highly correlated with severity of, and prognosis in, heart failure. BNP testing is routinely performed at the cardiac clinic at University Health Network to determine treatment response and to assist with risk stratification prognostication in patients with heart failure.
|Study Start Date:||August 2013|
|Estimated Study Completion Date:||December 2016|
|Estimated Primary Completion Date:||August 2016 (Final data collection date for primary outcome measure)|
Patients identified with primary and secondary carnitine deficiency in the cardiomyopathy population will be prescribed with carnitine supplements to assess cardiac muscle function and status.
Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
Other Name: Carnitor
The primary objective of this research is to determine the prevalence of primary and secondary (genetic and acquired) carnitine deficiency in patients with limb girdle weakness and hypertrophic or idiopathic dilated cardiomyopathy where an underlying cause is unknown. Identification and treatment with carnitine may potentially reverse or halt heart failure and skeletal muscle weakness in these patients.
- To ascertain the prevalence of primary and secondary carnitine deficiency in a population of adults with myopathy and hypertrophic and dilated cardiomyopathy of unknown etiology
- To describe the demographic and phenotypic characteristics of patients with myopathy and dilated or hypertrophic cardiomyopathy who have primary and secondary carnitine deficiency
- To measure the motor and cardiovascular response to carnitine supplementation in patients with myopathy, cardiomyopathy and carnitine deficiency
Please refer to this study by its ClinicalTrials.gov identifier: NCT01904396
|Contact: Hanna Faghfouryfirstname.lastname@example.org|
|University Health Network||Not yet recruiting|
|Toronto, Ontario, Canada|
|Principal Investigator: Hanna Faghfoury, MD|
|Principal Investigator:||Faghfoury Hannaneh, MD||University Health Network, Toronto, Ontario|
|Principal Investigator:||Ingrid Tein, MD||The Hospital for Sick Children, Toronto, Ontario|